Will they co-crystallize? by Wicker, Jerome G. P. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Will they co-crystallize?
Author(s) Wicker, Jerome G. P.; Crowley, Lorraine M.; Robshaw, Oliver; Little,
Edmund J.; Stokes, Stephen P.; Cooper, Richard I.; Lawrence, Simon E.
Publication date 2017
Original citation Wicker, J. G. P., Crowley, L. M., Robshaw, O., Little, E. J., Stokes, S.
P., Cooper, R. I. and Lawrence, S. E. (2017) 'Will they co-crystallize?',
CrystEngComm, 19(36), pp. 5336-5340. doi: 10.1039/c7ce00587c






Access to the full text of the published version may require a
subscription.
Rights © 2017, The Royal Society of Chemistry. This article is licensed
under a Creative Commons Attribution 3.0 Unported Licence.
Material from this article can be used in other publications provided











Simon E. Lawrence et al.
Will they co-crystallize?
Volume 19 Number 36 28 September 2017 Pages 5315–5494
CrystEngComm
COMMUNICATION
Cite this: CrystEngComm, 2017, 19,
5336
Received 27th March 2017,




Jerome G. P. Wicker, a Lorraine M. Crowley, b Oliver Robshaw,a Edmund J. Little,a
Stephen P. Stokes,b Richard I. Cooper a and Simon E. Lawrence *b
A data-driven approach to predicting co-crystal formation reduces
the number of experiments required to successfully produce new
co-crystals. A machine learning algorithm trained on an in-house
set of co-crystallization experiments results in a 2.6-fold enrich-
ment of successful co-crystal formation in a ranked list of co-for-
mers, using an unseen set of paracetamol test experiments.
Co-crystals are multi-component crystalline materials that can
be assembled via hydrogen bonds,1–5 halogen bonds6–8 and/
or π⋯π stacking.9,10 Co-crystallization has attracted academic
and industrial interest because it allows the physiochemical
properties of active pharmaceutical ingredients (APIs) to be al-
tered, for example bioavailability and solubility,11,12 com-
pressibility,13 hygroscopic stability,14 intrinsic dissolution
rate,15 and thermal properties.16
The four most common hydrogen bond supramolecular
synthons used in the design-phase of co-crystallization stud-
ies are shown in Fig. 1.17 For a hydrogen-bonded co-crystal to
form, there must be a degree of complementarity between
the two components (co-formers), thus, careful co-former se-
lection is crucial.18,19 The hierarchical nature of supramolec-
ular synthons is considered a key factor in accessing hetero-
meric interactions in the solid state. The work of Margaret
Etter is fundamental in our understanding of hydrogen bond
hierarchy.20,21
In addition to ‘Etter's rules’, Hunter reported a set of nu-
merical guidelines for quantifying the molecular interactions
of organic molecules in the solid state, by assigning hydrogen
bond strength parameters based on calculations of the mo-
lecular electrostatic potential surface to hydrogen bond do-
nors and acceptors.22 Since the strongest donors and accep-
tors are likely to hydrogen bond with each other,21 a
hierarchical list of these can be used to predict the interac-
tion energy for each pairing until all possible contacts have
been made, with excess donors or acceptors ignored. The
sum of these interaction energies gives a measure of the sta-
bility of a co-crystal relative to the pure components without
any knowledge of three-dimensional structure.23 This ap-
proach provides an estimate of the probability of a co-crystal
forming, allowing a set of potential crystal co-formers to be
ranked and has been shown to be able to identify new co-
crystals.
Previous methods to predict co-crystal formation have fo-
cussed on comparison of melting points of the co-crystal and
the pure components,16 or co-crystal structure prediction.24
However, such methods are computationally expensive and
require significant calculation for each new set of potential
co-crystal components, since the method requires generation
of trial structures. It has also been reported that effective co-
crystal screening can be achieved using a fluid-phase thermo-
dynamics model to calculate the excess enthalpy of the inter-
actions between a mixture of API and co-former relative to
the pure components in a virtually supercooled liquid
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mixture (which can be approximated to the mixed solid
phase crystal).25
Experimentally, determination of new co-crystals involves
systematic screening with a large range of co-formers, typi-
cally analysed via IR, DSC, and powder X-ray diffraction
(PXRD), with single crystal X-ray diffraction used if possible.
Although this approach is effective, it is costly in both time,
effort and laboratory resources, particularly when considering
the number of failed attempts in a traditional co-crystal
screen.
Statistical analysis of the descriptors of components of co-
crystal structures extracted from the Cambridge Structural
Database (CSD) has uncovered correlations between the
shape and polarity of co-formers,26 but the lack of data on
failed co-crystallization experiments mean that no predictive
model has been derived from this to date.
A knowledge-based method based on hydrogen bond pro-
pensity (HBP) analysis27 of the CSD28 to determine the likeli-
hood of co-crystal formation by assessing the probability of
the homo- and hetero-interactions has been shown to suc-
cessfully identify some co-crystals of paracetamol.29
Machine learning algorithms can be used to produce pre-
dictive empirical models from suitable data and have previ-
ously been applied to successfully predict whether small or-
ganic molecules will or will not crystallize, using molecular
descriptors calculated from a two-dimensional representation
of a molecule.30 More recently, artificial neural networks have
been successfully applied to predict the melting points of co-
crystals.31 Such data-driven approaches have not been used
to directly predict co-crystal formation.
In this paper, we report the use of a machine learning al-
gorithm to generate a predictive model which can classify
pairs of co-formers as successful or unsuccessful with respect
to co-crystallization using simple descriptors of the co-former
molecules. Estimates of the potential success of a particular
pair of co-formers can be used to generate a ranked list that
will enrich the identification of experimentally-determined
successful co-formers at the top of the list.
Since the literature contains almost exclusively positive re-
sults for co-crystallization studies, it was necessary to gener-
ate a landscape of both positive and negative experimental
data to support the training of the machine learning algo-
rithm. A set of 20 target molecules was initially selected to be
screened against 34 substituted aromatic acid and amide co-
formers (Fig. 2 and 3). Careful consideration was given in the
selection process to incorporate the potential for the four
main supramolecular synthons (Fig. 1). Assessment of co-
crystal formation was based upon changes in the PXRD pat-
tern when accompanied in IR by a shift of the characteristic
peaks traditionally involved in hydrogen bonding. In some
cases, DSC was also used to assess co-crystal formation. Ex-
perimental data for all three techniques are in the ESI.†
191 standard molecular descriptors were calculated for
each compound using the RDKit cheminformatics toolkit,
version Q1 2016.32 The descriptors for certain amine, amide
and ether functional groups were slightly modified to
uniquely identify the functional groups in more complex mol-
ecules, while additional descriptors were added to account
for aryl halides. This gave a total of 195 descriptors for each
co-former compound, see ESI.† Co-crystal descriptors were
created by concatenating the co-former descriptors and the
acid or amide descriptors along with an extra descriptor
implementing the values developed by Hunter22 This gave a
total of 391 descriptors for each potential co-crystal.
The label “1” was assigned to known or experimentally de-
termined co-crystals or salts and the label “0” assigned to
those experiments that did not result in a new solid form.
Those combinations for which the outcome was uncertain
were removed from the dataset, giving a total of 657 training
data points (403 unsuccessful, 254 successful). Of these 254
successful data points, 44 were already reported in the litera-
ture (39 co-crystals and 5 salts) and the remaining 210 repre-
sent novel solid forms. We are confident that this training
data is a useful set for predicting co-crystal formation due to
the low number of salts found in the CSD, and the low suc-
cess of salt formation from dry grinding, although the likeli-
hood of co-crystal over salt formation can be assessed by
comparing co-former and API pKa values.
33
Machine learning algorithms and performance metrics
from version 17.0 of the scikit-learn package were used.34
Support vector machines (SVMs) were used as the machine
Fig. 2 Co-former molecules used in this study.
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learning algorithm to create the predictive model using the
molecular descriptors, having previously been found to give
the best performance for a similar classification problem.30
The best-performing parameters for the algorithm were deter-
mined by a grid-search of parameters using a five-fold cross-
validation on the entire training dataset35 and were subse-
quently fixed at values of C = 10 and gamma = 0.001. A bal-
anced class weighting was used to account for the potential
bias caused by the greater number of unsuccessful co-crystal
experiments in the training set.
An external validation set was created from Wood et al.,
which collated paracetamol studies from a variety of
sources.29,36–38 This gave a total of 34 potential co-formers, of
which 13 successfully formed co-crystals.‡ The descriptors
were calculated in the same way as for the training set.
In addition to the classification accuracy on the validation
set, the capability of the approach to “enrich” the number of
successful hits in a ranked list was calculated, since this has
practical application in reducing the number of experiments
required to find co-crystal forms. For the external validation
set, the co-crystals were ranked according to the probability
estimate given by the predictive model. This was compared
to the actual hits in order to quantify how many successful
co-crystals were identified by this selection method. From
this ranking, an enrichment factor (EF) provides a numerical
score that quantifies the observed success rate at the top of
the list relative to randomly sampling the list. For the top x%
of the ranked list:
where Nhits is the number of hits in the top x%, Nx is the to-
tal number of successful and unsuccessful co-crystals in the
top x%, Ntotal hits is the number of hits in the whole list and
Ntotal is the total number of successful and unsuccessful co-
formers in the whole list.
The probability estimates from the predictive models were
also used to generate a receiver operating characteristic
(ROC) curve for the validation set classification, which mea-
sures the ability of the model to rank the successful co-
crystals relative to the unsuccessful ones.39 The area under
the curve (AUC) provides a quantitative measure of the accu-
racy of the ranking.39,40
The predictive accuracy of the model in classifying the co-
formers as forming successful or unsuccessful co-crystals with
paracetamol was poor at 64.7%, much lower than the cross-
validation accuracy on the training set (75.0% ± 1.4%). The
confusion matrix (Table 1) shows that the model has a ten-
dency towards predicting more of the combinations as being
successful co-crystals, which reduces the number of false nega-
tives (successful co-crystals that are incorrectly marked as un-
likely to form and so would be missed). This may be a result
of differences between paracetamol and the co-formers mak-
ing up the training set, which could affect the reliability of the
probability cut-off that the model uses to make its predictions.
However, Fig. 4 shows that the list of co-formers ranked by
the probabilities obtained from the model successfully iden-
tifies 9 of the 13 co-crystals of paracetamol within the top 11
suggestions in the list. The AUC of 0.85 is significantly better
than the AUC of 0.66 obtained from the HBP method,29 as
shown in Fig. 5. This gave an EF25 of 2.6, corresponding to
100% successful prediction in the top 8 (25%). This suggests
that although the probability cut-off between successful and
failed co-crystals used by the algorithm to perform the binary
classification may be wrongly positioned, the probability rank-
ing itself provides a way of identifying co-formers which are
likely to form co-crystals, reducing the number of experiments
required to successfully identify co-former pairings.
The importance of ensuring that co-former molecules lie in a
similar area of chemical space to the molecules used for train-
ing the model is illustrated by salsalate, for which the current
model predicts the same probability of co-crystal formation re-
gardless of the co-former paired with it. On examination of the
scaled descriptors, 39 salsalate descriptors are found to have
values greater than 3 standard deviations from the mean of the
training set (compared to 5 descriptors for paracetamol). This is
an indicator that the distance between salsalate and the training
molecules in chemical space is too great for the model to pro-
vide a sensible prediction. Consequently the descriptors of test
molecules need to be examined carefully after scaling to ensure
that the existing model is suitable for use with that particular
Table 1 Confusion matrix of model with paracetamol
Predicted co-crystal Predicted no co-crystal
Co-crystal formed 12 true positive 1 false negative
No co-crystal formed 11 false positive 10 true negative
Fig. 4 Probability ranking by the model for the paracetamol external
validation set. Green dots indicate successful co-crystals, whereas
unsuccessful co-formers are represented as red dots. More informa-
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molecule, and extension of the training set to sample a more ap-
propriate area of chemical space should be considered if this is
not the case.
The ability of the model to successfully rank co-formers
other than those included in the training dataset indicates
that the co-formers and descriptors used to train the model
provide enough information to allow the model to be applied
to a wide range of co-formers. Increasing the scope of the
model can be envisaged by retraining the algorithm using a
larger range of APIs and co-formers.
In comparison to other methods used for predicting the
ability of molecules to co-crystallize together,26,29 this ap-
proach requires a large amount of experimental work to be
undertaken to generate the initial training set. Academic and
industrial researchers in the field will have access to previous
experimental data containing both successful and unsuccess-
ful results, meaning that this will not hinder the implementa-
tion of this methodology.
In summary, we have demonstrated that a machine learn-
ing algorithm trained on an in-house set of co-crystallization
experiments using simple descriptors as the input can be
used to guide selection of co-formers for a particular API.
This is likely to assist industry by saving both time and re-
sources on experimental screens, particularly in the early
stages of co-former selection.
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Notes and references
‡ The CCDC numbers for the 13 crystals that were successfully structurally
characterised are: 1538729 (nicotinamide and 4-nitrobenzoic acid), 1538730 (nic-
otinamide and 4-fluorobenzoic acid), 1538731 (isonicotinamide and
3-methyoxybenzoic acid), 1538732 (urea and 3-nitrobenzoic acid), 1538733 (iso-
nicotinamide and 2-aminobenzoic acid), 1538734 (benzamide and
3-fluorobenzoic acid), 1538735 (nicotinamide and 2-nitrobenzoic acid), 1538736
(nicotinamide and 3-methylbenzoic acid), 1538737 (4,4′-bipyridyl and
2-fluorobenzoic acid), 1538738 (benzamide and 2-nitrobenzoic acid), 1538739
(urea and 2-nitrobenzoic acid), 1538740 (nicotinamide and 2-aminobenzoic acid)
and 1538741 (isonicotinamide and 2-nitrobenzoic acid).
Crystal data for 1538729: C13H11N3O5, Mr = 289.25, triclinic, P1̄, a = 7.1167(5) Å,
b = 7.5590(5) Å, c = 12.8081(9) Å, α = 85.164Ĳ2)°, β = 75.933Ĳ2)°, γ = 85.895Ĳ2)°, V
= 665.04(8) Å3, Z = 2, T = 296.(2) K, 19325 reflections collected, 2718 unique (Rint
= 0.0344), final GooF = 1.023, R1 = 0.0397 [2064 obs. data: I > 2σ(I)], wR2 =
0.1159 (all data).
Crystal data for 1538730: C13H11FN2O3, Mr = 262.24, monoclinic, P21/c, a =
13.629(16) Å, b = 7.151(8) Å, c = 13.651(15) Å, β = 115.649Ĳ17)°, V = 1199.0(2) Å3,
Z = 4, T = 296(2) K, 6819 reflections collected, 2463 unique (Rint = 0.0286), final
GooF = 1.029, R1 = 0.0392 [1764 obs. data: I > 2σ(I)], wR2 = 0.1135 (all data).
Crystal data for 1538731: C22H22N2O7, Mr = 426.41, triclinic, P1̄, a = 10.443(8) Å,
b = 12.603(11) Å, c = 17.396(16) Å, α = 110.90Ĳ2)°, β = 98.50Ĳ2)°, γ = 90.185Ĳ19)°, V
= 2112(3) Å3, Z = 4, T = 296(2) K, 36421 reflections collected, 8786 unique (Rint =
0.0494), final GooF = 1.011, R1 = 0.0657 [4679 obs. data: I > 2σ(I)], wR2 = 0.2070
(all data).
Crystal data for 1538732: C8H9N3O5, Mr = 227.18, monoclinic, P21/c, a = 8.084(4)
Å, b = 12.756(6) Å, c = 9.490(4) Å, β = 93.543Ĳ12)°, V = 976.7(8) Å3, Z = 4, T =
296(2) K, 7065 reflections collected, 1904 unique (Rint = 0.0580), final GooF =
0.997, R1 = 0.0712 [1134 obs. data: I > 2σ(I)], wR2 = 0.2452 (all data).
Crystal data for 1538733: C13H13N3O3, Mr = 259.26, monoclinic, P21/c, a =
12.516(5) Å, b = 10.899(4) Å, c = 9.306(3) Å, β = 95.296Ĳ12)°, V = 1264.0(8) Å3, Z =
4, T = 300(2) K, 19310 reflections collected, 2225 unique (Rint = 0.1923), final
GooF = 1.015, R1 = 0.0853 [1007 obs. data: I > 2σ(I)], wR2 = 0.2536 (all data).
Crystal data for 1538734: C14H12FNO3, Mr = 261.25, triclinic, P1̄, a = 5.222(4) Å,
b = 8.817(7) Å, c = 14.578(11) Å, α = 101.606Ĳ18)°, β = 94.434Ĳ16)°, γ =
94.826Ĳ18)°, V = 652.1(9) Å3, Z = 2, T = 300(2) K, 8127 reflections collected, 2397
unique (Rint = 0.0768), final GooF = 0.974, R1 = 0.0716, [1013 obs. data: I >
2σ(I)]; wR2 = 0.2046 (all data).
Crystal data for 1538735: C20H16N4O9, Mr = 456.37, monoclinic, C2/c, a =
27.715(3) Å, b = 7.0371(7) Å, c = 21.947(2) Å, β = 105.132Ĳ4)°, V = 4132.0(7) Å3, Z =
8, T = 300(2) K, 22442 reflections collected, 3633 unique (Rint = 0.0431), final
GooF = 1.019, R1 = 0.0401 [2875 obs. data: I > 2σ(I)], wR2 = 0.1092 (all data).
Crystal data for 1538736: C22H22N2O5, Mr = 394.41, monoclinic, P21/n, a =
10.878(3) Å, b = 12.704(4) Å, c = 15.328(5) Å, β = 107.034Ĳ9)°, V = 2025.3(11) Å3, Z
= 4, T = 300(2) K, 37173 reflections collected, 3550 unique (Rint = 0.1220), final
GooF = 1.036, R1 = 0.0672 [1651 obs. data: I > 2σ(I)], wR2 = 0.2008 (all data).
Crystal data for 1538737: C17H13FN2O2, Mr = 296.29, monoclinic, P21/n, a =
11.012(2) Å, b = 4.0528(8) Å, c = 32.335(6) Å, β = 94.648Ĳ4)°, V = 1438.3(5) Å3, Z =
4, T = 296(2) K, 21090 reflections collected, 2944 unique (Rint = 0.0370), final
GooF = 1.044, R1 = 0.0589 [2002 obs. data: I > 2σ(I)], wR2 = 0.2075 (all data).
Crystal data for 1538738: C21H17N3O9, Mr = 455.38, triclinic, P1̄, a = 7.988(3) Å, b
= 11.004(5) Å, c = 12.725(6) Å, α = 73.939Ĳ10)°, β = 75.605Ĳ10)°, γ = 89.042Ĳ11)°, V
= 1039.5(8) Å3, Z = 2, T = 300(2) K, 17332 reflections collected, 4182 unique (Rint
= 0.804), final GooF = 0.909, R1 = 0.0657, [1843 obs. data: I > 2σ(I)]; wR2 = 0.2499
(all data).
Crystal data for 1538739: C15H14N4O9, Mr = 394.30, monoclinic, P21/n, a =
11.8242Ĳ18) Å, b = 10.0350Ĳ15) Å, c = 15.060(2) Å, β = 104.953Ĳ2)°, V = 1726.4(4)
Å3, Z = 4, T = 296(2) K, 22669 reflections collected, 3077 unique (Rint = 0.0288), fi-
nal GooF = 1.038, R1 = 0.0366 [2530 obs. data: I > 2σ(I)], wR2 = 0.1012 (all data).
Crystal data for 1538740: C13H11N3O3, Mr = 259.26, monoclinic, P21, a =
Fig. 5 Receiver operating characteristic curves for the paracetamol
validation set. The blue line is this work, the green line uses the
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10.479(2) Å, b = 4.9873(9) Å, c = 12.644(3) Å, β = 109.361Ĳ5)°, V = 623.4(2) Å3, Z =
2, T = 296(2) K, 9087 reflections collected, 2364 unique (Rint = 0.0278), final
GooF = 1.040, R1 = 0.0305 [2141 obs. data: I > 2σ(I)], wR2 = 0.0746 (all data). Re-
fined as a 2-component inversion twin.
Crystal data for 1538741: C26H22N6O10, Mr = 578.49, monoclinic, P21/c, a =
8.873(2) Å, b = 34.245(8) Å, c = 9.175(2) Å, β = 105.942Ĳ8)°, V = 2680.7(11) Å3, Z =
4, T = 300(2) K, 29445 reflections collected, 4734 unique (Rint = 0.0540), final
GooF = 1.046, R1 = 0.0469 [3588 obs. data: I > 2σ(I)], wR2 = 0.1394 (all data).
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